Literature DB >> 21742004

Evaluation of serotype-specific pneumococcal IgG measurement using two different polysaccharides from ATCC and SSI Diagnostica.

Hans-Christian Slotved1, Bjørn Kantsø, Mette B Kerrn, Ian C Skovsted, Charlotte S Jørgensen.   

Abstract

Streptococcus pneumoniae (pneumococcus) is a major cause of morbidity and mortality especially in infants and elderly people. Pneumococcus capsular polysaccharide has been characterised and more than 90 different serotypes have been identified. Serotype-specific antibodies against the capsular polysaccharide are produced during infection. At present, many countries follow the WHO pneumococcal ELISA IgG measurement protocol, in which polysaccharides from ATCC are used as antigens. In recent years, serotype specific polysaccharides from different producers have been tested in pneumococcal antibody assay's. In this project, purified serotype specific pneumococcal antigens from SSI Diagnostica and from ATCC were compared. In general, the data showed that both types of polysaccharide could be used as antigens. Furthermore, the effect of adsorption using different combinations of adsorption procedures was tested, showing similar results using CWPSmulti or CWPS+22F.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742004     DOI: 10.1016/j.vaccine.2011.06.102

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  1 in total

1.  Multilaboratory Comparison of Pneumococcal Multiplex Immunoassays Used in Immunosurveillance of Streptococcus pneumoniae across Europe.

Authors:  Bob Meek; Nina Ekström; Bjørn Kantsø; Rachael Almond; Jamie Findlow; Jenna F Gritzfeld; Charlotte Sværke Jørgensen; Karl Ljungberg; Fredrik Atterfelt; Manou R Batstra; Kevin Andeweg; Ben A W de Jong; Harry E Prince; Mary Lapé-Nixon; Pieter G M Gageldonk; Irina Tcherniaeva; Ingeborg Aaberge; Tove Karin Herstad; Merit Melin; Ger T Rijkers; Guy A Berbers
Journal:  mSphere       Date:  2019-11-27       Impact factor: 4.389

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.